FDA approvals and rejections for new drugs and devices with the condition and the label, upcoming PDUFA dates and advisory committee meetings, expanded access and compassionate use program openings, phase 3 trial enrollment openings for major conditions with locations, accelerated approval withdrawals, and manufacturer patient assistance program launches, with the drug and the condition first.